Drug intelligence / Profile preview

ProPrems

Development stage: Unknown
Lead developer: Neobiomics
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

ProPrems is a specific multi-strain probiotic formulation consisting of *Bifidobacterium infantis* (strain Bb-02), *Bifidobacterium lactis* (strain Bb-12), and *Streptococcus thermophilus* (strain TH-4). It was developed primarily for use in the ProPrems trial, a large-scale multicenter randomized controlled trial conducted in Australia and New Zealand to evaluate the efficacy of probiotics in preventing necrotizing enterocolitis (NEC) in very preterm infants (born at less than 32 weeks' gestation and weighing less than 1500g). The mechanism of action involves the competitive exclusion of pathogenic bacteria, enhancement of the intestinal epithelial barrier function, and modulation of the immature mucosal immune system. By establishing a healthy commensal microbiota, ProPrems aims to reduce the incidence of NEC and late-onset sepsis, which are significant causes of morbidity and mortality in the neonatal intensive care unit.

Brand names: ProPrems
Other names: Bb-02 + Bb-12 + TH-4

Beyond the preview

Go deeper on ProPrems.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProPrems.

Explore the full profile